An FC-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia

International Journal of Cancer

Volumn 136, Issue 5, 2015, Pages 1073-1084

  Steinbacher, Julia ^a   Baltz Ghahremanpour, Katrin ^a   Schmiedel, Benjamin Joachim ^a   Steinle, Alexander ^b   Jung, Gundram ^a,c   Kübler, Ayline ^d   André, Maya Caroline ^d,e   Grosse Hovest, Ludger ^a   Salih, Helmut Rainer ^a,c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

ADCC; Leukemia; NK cells; NKG2D ligands

Indexed keywords

CD69 ANTIGEN; GAMMA INTERFERON; HYBRID PROTEIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D IMMUNOGLOBULIN G PROTEIN; NATURAL KILLER CELL RECEPTOR NKG2DL; RITUXIMAB; UNCLASSIFIED DRUG; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; KLRK1 PROTEIN, HUMAN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K;

AMINO ACID SUBSTITUTION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE RELEASE; DEGRANULATION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; INTERFERON PRODUCTION; LYMPHATIC LEUKEMIA; NATURAL KILLER CELL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; CYTOTOXICITY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LEUKEMIA; PATHOLOGY;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LEUKEMIA; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECOMBINANT FUSION PROTEINS;

EID: 84918790407     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29083     Document Type: Article

References (50)

1. Keating GM. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 2010;70:1445-76.
2. Arteaga CL, Sliwkowski MX, Osborne CK, et al. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2012;9:16-32.
3. Beck A, Wurch T, Bailly C, et al. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010;10:345-52.
4. Oflazoglu E, Audoly LP. Evolution of anti-CD20 monoclonal antibody therapeutics in oncology. MAbs 2010;2:14-9.
5. De Haij S, Jansen JHM, Boross P, et al. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res 2010;70:3209-17.
6. Lazar GA, Dang W, Karki S, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 2006;103:4005-10.
7. Foyil KV, Bartlett NL. Anti-CD30 Antibodies for Hodgkin lymphoma. Curr Hematol Malig Rep 2010;5:140-7.
8. Horton HM, Bernett MJ, Pong E, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res 2008;68:8049-57.
9. Horton HM, Bernett MJ, Peipp M, et al. Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies. Blood 2010;116:3004-12.
10. Owen C, Stewart DA. Obinutuzumab for the treatment of lymphoproliferative disorders. Expert Opin Biol Ther 2012;12:343-51.
11. Feldman EJ, Brandwein J, Stone R, et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or firstrelapsed acute myeloid leukemia. J Clin Oncol 2005;23:4110-6.
12. Vivier E, Tomasello E, Baratin M, et al. Functions of natural killer cells. Nat Immunol 2008;9:503-10.
13. Seidel UJ, Schlegel P, Lang P. Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front Immunol 2013;4:76.
14. Moretta L, Locatelli F, Pende D, et al. Human NK receptors: from the molecules to the therapy of high risk leukemias. FEBS Lett 2011;585:1563-7.
15. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097-100.
16. Lowdell MW, Craston R, Samuel D, et al. Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. Br J Haematol 2002;117:821-7.
17. Pierson BA, Miller JS. CD561bright and CD561dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis. Blood 1996;88:2279-87.
18. Tajima F, Kawatani T, Endo A, et al. Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia. Leukemia 1996;10:478-82.
19. Orr MT, Lanier LL. Natural killer cell education and tolerance. Cell 2010;142:847-56.
20. Raulet DH, Gasser S, Gowen BG, et al. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 2013;31:413-41.
21. Hilpert J, Grosse-Hovest L, Grünebach F, et al. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J Immunol 2012;189:1360-71.
22. Armour KL, Clark MR, Hadley AG, et al. Recombinant human IgG molecules lacking Fc gamma receptor I binding and monocyte triggering activities. Eur J Immunol 1999;29:2613-24.
23. Nimmerjahn F, Ravetch JV. Fc gamma receptors as regulators of immune responses. Nat Rev Immunol 2008;8:34-47.
24. Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 2012;119:5640-9.
25. Bryceson YT, Ljunggren HG. Tumor cell recognition by the NK cell activating receptor NKG2D. Eur J Immunol 2008;38:2957-61.
26. Schmiedel BJ, Scheible CA, Nuebling T, et al. RANKL expression, function, and therapeutic targeting in multiple myeloma and chronic lymphocytic leukemia. Cancer Res 2013;73:683-94.
27. Schmiedel BJ, Werner A, Steinbacher J, et al. Generation and preclinical characterization of a Fc-optimized GITR-Ig fusion protein for induction of NK cell reactivity against leukemia. Mol Ther 2013;21:877-86.
28. Armeanu S, Krusch M, Baltz KM, et al. Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma. Clin Cancer Res 2008;14:3520-8.
29. Krusch M, Salih J, Schlicke M, et al. The kinase inhibitors sunitinib and sorafenib differentially affect NK Cell antitumor reactivity in vitro. J Immunol 2009;183:8286-94.
30. Buechele C, Baessler T, Schmiedel BJ, et al. 4-1BB ligand modulates direct and Rituximabinduced NK-cell reactivity in chronic lymphocytic leukemia. Eur J Immunol 2012;42:737-48.
31. Salih HR, Antropius H, Gieseke F, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003;102:1389-96.
32. Bowles JA, Weiner GJ. CD16 polymorphisms and NK activation induced by monoclonal antibodycoated target cells. J Immunol Methods 2005;304:88-99.
33. Salih HR, Rammensee HG, Steinle A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 2002;169:4098-102.
34. Tran L, Baars JW, Aarden L, et al. Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. Hum Antibodies 2010;19:7-13.
35. Ma Y, Lin BR, Lin B, et al. Pharmacokinetics of CTLA4Ig fusion protein in healthy volunteers and patients with rheumatoid arthritis. Acta Pharmacol Sin 2009;30:364-71.
36. Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011;331:44-9.
37. Spear P, Wu MR, Sentman ML, et al. NKG2D ligands as therapeutic targets. Cancer Immun 2013;13:8.
38. Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010;47:115-23.
39. Bryceson YT, March ME, Ljunggren HG, et al. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 2006;107:159-66.
40. Bryceson YT, Ljunggren HG, Long EO. Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors. Blood 2009;114:2657-66.
41. Harada S, Kimura T, Fujiki H, et al. Flt3 ligand promotes myeloid dendritic cell differentiation of human hematopoietic progenitor cells: Possible application for cancer immunotherapy. Int J Oncol 2007;30:1461-8.
42. Zhang T, Barber A, Sentman CL. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor. Cancer Res 2006;66:5927-33.
43. Zhang T, Barber A, Sentman CL. Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways. Cancer Res 2007;67:11029-36.
44. Kershaw MH, Westwood JA, Darcy PK. Geneengineered T cells for cancer therapy. Nat Rev Cancer 2013;13:525-41.
45. Koene HR, Kleijer M, Algra J, et al. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997;90:1109-14.
46. Shiokawa M, Takahashi T, Murakami A, et al. In vivo assay of human NK-dependent ADCC using NOD/SCID/gammac (null) (NOG) mice. Biochem Biophys Research Commun 2010;399:733-7.
47. Baessler T, Krusch M, Schmiedel BJ, et al. Glucocorticoidinduced tumor necrosis factor receptorrelated protein ligand subverts immunosurveillance of acute myeloid leukemia in humans. Cancer Res 2009;69:1037-45.
48. Buechele C, Baessler T, Wirths S, et al. Glucocorticoidinduced TNFR-related protein (GITR) ligand modulates cytokine release and NK cell reactivity in chronic lymphocytic leukemia (CLL). Leukemia 2011;26:991-1000.
49. Jaglowski SM, Alinari L, Lapalombella R, et al. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood 2010;116:3705-14.
50. Parkhurst MR, Riley JP, Dudley ME, et al. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res 2011;17:6287-97.